Our group previously shown the therapeutic promise of iNSC‐mediated delivery of TRAIL,16, 18, 28 a cytotoxic peptide that initiates apoptosis through interactions with death receptors 4 (DR4) and 5 (DR5),34 which are highly expressed on GBM tumor cells.35 This evidence concerns the gene TNFRSF10A and glioblastoma.